Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of ELDN is 7.5 and suggests 249% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell